In healthy women ≥ 45 years of age, how effective is aspirin in preventing cancer?
C o n c l u s i o n
In healthy women ≥ 45 years of age, lowdose aspirin did not prevent total cancer or breast, colorectal, or other types of cancer. C o m m e n t a r y 2 studies by Cook and Lee and their colleagues complete the reporting of primary outcomes from the Women's Health Study, a trial of lowdose aspirin and high-dose α-tocopherol in the primary prevention of CVD and cancer in generally healthy female health care professionals.
The 10-year results were fairly convincingly negative, with no hint of a benefit for either intervention in the primary endpoints. So many comparisons were made examining secondary outcomes and subgroups that caution is needed in interpreting any of these marginally significant findings, such as vitamin E reducing CV death or aspirin increasing cancer in never-smokers. The question then becomes, to whom and to what interventions do these results apply? Although all healthy women in the health care professions > 45 years of age were eligible, only 10% of the participants were > 65 years. Thus, it may be hard to apply these results to older women. Subgroup analysis suggested a benefit in the older age group with both vitamin E and low-dose aspirin (1) in the prevention of CVD. Doses of aspirin higher than the 100 mg every other day that was tested in the study by Cook and colleagues might decrease the incidence of colorectal cancer (2, 3) but would be expected to carry greater toxicity. The finding that α-tocopherol supplements had no benefit or might even increase mortality (4) is at odds with well-established epidemiologic data regarding diets high in vitamin E, including α-tocopherol and other antioxidants. Postulated causes include the displacement of other antioxidants, such as γ-tocopherol by α-tocopherol supplements (5) . The observational epidemiologic data also reflect uncontrolled confounding by other factors (e.g., healthy diet).
(continued on page 9) Note: This is a two-article spread with a shared commentary. Please scroll down for the second article. Outcomes: A composite endpoint of first major CV event (nonfatal myocardial infarction [MI], stroke, or CV death), and total invasive cancer excluding nonmelanoma skin cancer. Secondary outcomes were individual CV events and main site-specific types of cancer (breast, lung, and colon). Patient follow-up: 97% for morbidity and 99% for mortality (intention-to-treat analysis).
Q u e s t i o n

M a i n r e s u l t s
Vitamin E did not reduce the composite endpoint of first major CV event and did not reduce total invasive cancer more than placebo (Table) . 
C o m m e n t a r y (continued from page 8)
The bottom line for clinicians is that, for healthy women 45 to 64 years of age (who represented 90% of the participants in these 2 studies), there is no substantial benefit to long-term use of low-dose aspirin or high-dose vitamin E supplements. Studies specifically addressing these interventions in older women would be useful.
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